TAC+MMF + GC vs TAC +GC in lupus nephritis (target trial emulation): 🔹Higher total renal response w/ TAC + MMF + GC at 12 mo (59.7% vs 33.3%) consistent in ITT & per-protocol 🔹similar adverse events reported (14.6% vs 16.4%) @RheumNow #ACR25 https://t.co/Yuql3O9C8X

• https://x.com/AkhilSoodMD/status/1983590907095011839/photo/1

Sooner May Still Be Too Late: Kidney Biopsies in SLE #ACR25 kicked off with Plenary Session by Michelle Petri (Abstract 0772: Redefining When to Biopsy the Kidney in Patients with SLE. As part of a collaboration with the Accelerating Medicines Partnership, Petri and colleagues https://t.co/bU09vpcDew

#2659 In a large real-world target trial (>1.3M with T2D), SGLT2 inhibitors, esp dapagliflozin & empagliflozin, were assoc with lower risks of RA, lupus, vasculitis & other autoimmune rheumatic diseases vs DPP-4 inhibitors. Possible immune benefits of SGLT2i? @RheumNow #ACR25

#ACR25 Abstr#2697 H2H RCT of Tacrolimus + GC vs MMF + GC in #lupus Nephritis in Asia for Induction-Maintenance showed similar efficacy. Different side effects: AKI more in TAC, low WCC & infections in MMF. Informative for services with no access to biologics/Voclosporin @RheumNow https://t.co/V4uWhuqjjW

• https://x.com/Yuz6Yusof/status/1983578834315157825/photo/1

Abst 2694: Post-hoc analysis of Phase 2 PAISLEY SLE trial examined impact of deucravacitinib on renal dysfunction 🔹 Plasma proteins a/w ↑ BILAG renal score and ↓ UPCR --> reduced by WK 32 🔹 Biomarkers inversely related to eGFR were reduced with deucra vs PBO @RheumNow #ACR25 https://t.co/6CvmQ9lCfS

• https://x.com/AkhilSoodMD/status/1983576311118389425/photo/1
• https://x.com/AkhilSoodMD/status/1983576311118389425/photo/1

#ACR25 Clinical Preview by Prof Coates to be applied tomorrow! GC #steroid burden & Mx Abstr#738 Survey of #GCA patients in US & EU: 3/4 were still on GC; mean 5.3mg/d Abstr#1526 International consensus of GC taper in #SLE is available & can be applied in clinic @RheumNow https://t.co/paw7NGjs4p

• https://x.com/Yuz6Yusof/status/1983560828860465223/photo/1
• https://x.com/Yuz6Yusof/status/1983560828860465223/photo/1

Thank you @drdavidliew & @DrLauraCoates ❤️ for highlighting our work. Super-responders (some were IS-Free) do exist with rituximab in #SLE Abstr#1525 @RheumNow https://t.co/S4mMAYInfT

• https://twitter.com/drdavidliew/status/1983555936657854811

@Yuz6Yusof gets a shout out from Laura Coates in the #ACR25 meeting review for his work on rituximab super-responders in SLE @RheumNow https://t.co/EKUgmENesX

• https://x.com/drdavidliew/status/1983555936657854811/photo/1
• https://x.com/drdavidliew/status/1983555936657854811/photo/1

Year in Preview SLE: 52% subtherapeutic on weight based HCQ dosing Precision prescribing needed, more so for CKD @RheumNow #ACR25 Abstract 1722 https://t.co/8WqorQ1xJx

• https://x.com/JihaRheum/status/1983555467344310342/photo/1

Hydroxychloroquine in SLE is all about the sweet spot. Not too hot with retinopathy, not too cold with flares, just right by the levels. Yet drug concentrations and TDM are not commonplace in many places - time for change Laura Coates in the #ACR25 meeting review @RheumNow https://t.co/oB3ecfSQQc

• https://x.com/drdavidliew/status/1983555247269404896/photo/1

Turns out you can directly degrade NETs. Holy smokes NETs critical in pathology of SLE & other dx They’ve found you can target it Enzymatic degrader fused to albumin Proof-of-concept: degraded a patient’s SLE manifestations in hours Definitely one to watch #ACR25 LB22 @RheumNow https://t.co/HVEt8wFYmI

• https://x.com/drdavidliew/status/1983535986475974994/photo/1
• https://x.com/drdavidliew/status/1983535986475974994/photo/1
• https://x.com/drdavidliew/status/1983535986475974994/photo/1